New Study Demonstrates Non-Invasive Prenatal Testing in High-Risk Women at Price Point of $795 is Clinically Beneficial and Cost-Saving to the Healthcare System

SAN JOSE, Calif., Jan. 29, 2013 /PRNewswire/ -- A study in the Journal of Maternal-Fetal and Neonatal Medicine highlights the cost-effectiveness of non-invasive prenatal testing (NIPT) with cell-free DNA (cfDNA) in high-risk women.  NIPT was shown to have clinical benefit over conventional prenatal screening tests, and at a price point of $795, NIPT demonstrated cost savings to the healthcare system.

(Logo: http://photos.prnewswire.com/prnh/20130129/SF49467LOGO)

In the study, a decision analytic model was used to compare NIPT for trisomy 21, which causes Down syndrome, against conventional prenatal screening with first trimester combined or integrated screening for the U.S. population. While NIPT is not as comprehensive as a karyotype, it does not carry a risk of pregnancy loss. This is the first study to evaluate the economic impact of NIPT in a high-risk pregnancy population as recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal Fetal Medicine (SMFM).  As compared to conventional prenatal screening, NIPT detected 65-85% more cases of trisomy 21, reduced invasive procedures by over 95%, and in turn, reduced over 99% of unnecessary fetal loss.  Details of the study can be found at http://informahealthcare.com/doi/abs/10.3109/14767058.2013.770464

"The clinical advantages of implementing non-invasive prenatal testing into clinical practice are becoming increasingly clear and this model quantifies the benefit," said Dr. Aaron Caughey, senior author of the study and chair of Obstetrics and Gynecology at Oregon Health and Sciences University.  "One of the most striking findings is that NIPT can be cost saving to the U.S. healthcare system at the appropriate price.  Few, if any, new technologies can demonstrate both clinical and cost benefit.  NIPT represents a healthcare advance to achieve the Triple Aim of improved quality, better access, and lower costs."

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

SOURCE Ariosa Diagnostics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED